The Combination of Cyclin D1 and MRI Parameters Improves Breast Cancer Diagnosis and NACT Efficacy Assessment
Sažetak
Objective: The purpose of this study is to evaluate the combined diagnostic performance of Cyclin D1 and magnetic resonance imaging (MRI) parameters in breast cancer (BC), while also assessing their ability to forecast treatment response to neoadjuvant chemotherapy (NACT), so as to provide evidence for individualized treatment strategies.
Methods: This study recruited 154 BC patients and 148 healthy women. Peripheral blood Cyclin D1 quantification utilized enzyme-linked immunosorbent assay (ELISA), and CA15-3 and CA27.29 (both tumor markers) measurements were made using automated electrochemiluminescence immunoassay. Magnetic resonance imaging (MRI) was conducted to obtain dynamic contrast-enhanced scans, from which radiomics parameters (PSIER, TSICS, ADC) were derived. Diagnostic accuracy for BC and predictive value for chemotherapy response were evaluated through correlation analysis (Pearson), receiver operating characteristic (ROC) curves, and multivariate regression modeling.
Results: Cyclin D1 levels were elevated in BC patients compared to healthy controls and showed a positive connection with CA15-3 and CA27.29 (P<0.05). The diagnostic performance of Cyclin D1 alone yielded an AUC of 0.830, whereas a combined model incorporating MRI parameters (PSIER, TSICS, and ADC) significantly improved discrimination (AUC=0.935, sensitivity 86.36%, specificity 87.84%). During NACT, Cyclin D1 levels declined dynamically. A predictive model integrating Cyclin D1 and imaging biomarkers achieved an AUC of 0.775 for identifying poor NACT responders (sensitivity 88.37%, specificity 56.76%)
Conclusion: The combination of Cyclin D1 and MRI parameters enhances both BC diagnostic accuracy and NACT efficacy prediction.
Sva prava zadržana (c) 2025 Yufei Fu, Yizhi Shi, Zhen Wang, Xin Zhou
Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.